eGenesis
Vision
eGenesis strives to create a world with no shortage of human transplantable organs.
Approach
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. eGenesis is uniquely positioned to reinvigorate the field of xenotransplantation by addressing the key virology and immunology hurdles that have impeded its advancement to date.
eGenesis is addressing
CEO:
Mike Curtis
Founders:
Dr. Luhan Yang
Dr. George Church
First investment:
November 2019